Antiviral drugs and the treatment of hepatitis C

Current HIV/AIDS Reports

Volumn 9, Issue 2, 2012, Pages 132-138

  Jalali, Ziba ^a,c   Rockstroh, Jürgen K ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c Division of Infectious Disease   (United States)

Author keywords

Antiretroviral treatment; HCV treatment; HIV treatment; HIV HCV co infection; Nucleoside reverse transcriptase inhibitors; Pegylated interferon; Protease inhibitors; Ribavirin

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; BOCEPREVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HEMOGLOBIN; LAMIVUDINE; MARAVIROC; NEVIRAPINE; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; STAVUDINE; TELAPREVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE; ANTIRETROVIRUS AGENT; ENZYME INHIBITOR;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG DOSE REDUCTION; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; GLUCURONIDATION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSULIN RESISTANCE; LIVER FIBROSIS; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL TOXICITY; MIXED INFECTION; NEPHROTOXICITY; NONALCOHOLIC FATTY LIVER; TOXIC HEPATITIS; DRUG COMBINATION; REVIEW; VIROLOGY;

ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 84864008117     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0111-2     Document Type: Article

References (57)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and Adolescents. Department of Health and Human Services. 2009. p. 1-161. http://www.aidsinfo. nih.gov/contentfiles/AdultandAdolescentGL001419.pdf.
2. Joshi D, O'Grady J, Dietrich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198-209.
3. Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS Clinical (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9:82-8. (Pubitemid 351228130)
4. Brook G, Main J, Nelson MA, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C Virus. HIV Med. 2010;11:1-30.
5. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginter-feron alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-50. (Pubitemid 38988593)
6. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-48. (Pubitemid 39628231)
7. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22-31.
8. Nunez M, Miralles C, Berdun MA et al for the PRESCO study group. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retrovir 2007;23:972-82. (Pubitemid 47492337)
9. Rodriguez-Torres M, Slim J, Bhatti L, et al. On behalf of the PARADIGM Study Investigators: Peginterferon alfa-2A (40KD) plus 800 or 1000/1200 mg/day RBV in G1 HIV-HCV-Co-infection patients: early responses to treatment and predictability for SVR in PARADIGM study. Presented at the European Association for the Study of the Liver (EASL). Vienna, Austria, March 30-April 3, 2010.
10. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis-C-virus (HCV) associated liver disease in HIV-HCV coinfected hemophiliacs. Am J Gastroenterol. 1996;91:2563-8.
11. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet. 2003;362:1708-13. (Pubitemid 37468321)
12. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47-55. (Pubitemid 41772515)
13. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peg-interferon-alpha 2a (40 KD)+ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Def Syndr. 2008;47:36-49. (Pubitemid 351619367)
14. Weller IV, Williams IG ABC of AIDS. Antiretroviral drugs. BMJ. 2001;322:1410-2.
15. Alvarez D, Dieterich DT, Brau N, et al. Zidovudine use but not weight-based ribavirin dosing impacts anemia during HCV treatment in HIV infected persons. J viral Hepat. 2006;13:683-9. (Pubitemid 44401197)
16. Berenguer J, von Wichmann MA, Quereda C, et al. On behalf of the GESIDA 36/03 and 50/06 Study Groups.: Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. J Antimicrob Chemother. 2011;66:2843-9.
17. MacNicholas R, Norris S. Optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV-the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther. 2010;31:929-37.
18. Behler CM, Vittinghoff E, Lin F, et al. Hematological toxicity associated with interferon-based hepatitis C therapy in HIV type 1 coinfected patients. Clin Infect Dis. 2007;44:1375-83. (Pubitemid 46717302)
19. Mira J, Lopes-Cortes LF, Merino D, et al. Predictors of severe hematological toxicity secondary to pegylated interferon plus ribavirin treatment. Antiviral Ther. 2007;12:1225-35.
20. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-1. (Pubitemid 32120863)
21. Reiberger T, Kosi L, Maresch J, et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis. 2010;202:156-60.
22. Bani-Sadr F, Lapidus N, Bedossa P, et al. French National Agency for Research on AIDS. Viral Hepatitis-HC02-Ribavic Study Team.: Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis. 2008;46:768-74. (Pubitemid 351321564)
23. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read. 2003;13:344-8. (Pubitemid 36890378)
24. Mauss S, Valenti W, De Pamphillis J, et al. Risk factors for hepatic decompensation in patients with HIV-HCV co-infection and liver cirrhosis during interferon-based therapy. AIDS. 2004;18:21-5.
25. Perronne C. Antiviral Hepatitis and antiretroviral drug interactions. J Hepatol. 2006;44:119-25.
26. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-6. (Pubitemid 32268957)
27. Bani-Sadr, Lapidus N, Melchior JC, et al. Severe weight loss in HIV/HCV co-infected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepat. 2008;15:255-60.
28. Lo Re 3rd V, Kostman JR, Gross R, et al. Incidence and risk factors for weight loss during dual HIV/Hepatitis therapy. Acquire Immune Defic Syndr. 2007;44:344-50. (Pubitemid 46328353)
29. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with peg-IFN-RBV combination: does abacavir play a role? J Acquir Immune Defic Syndr. 2007;45:123-5. (Pubitemid 46684453)
30. Vispo E, Barreiro P, Pineda J, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13:429-37. (Pubitemid 352016736)
31. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Anit-vir Ther. 2008;13:953-7.
32. Amorosa VK, Slim J, Moinzer K, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther. 2010;15:91-9.
33. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13:429-37. (Pubitemid 352016736)
34. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricita-bine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60. (Pubitemid 43113030)
35. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482-7.
36. Rodriguez-Novoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010;9:545-59.
37. Quereda C, Corral I, Moreno A, et al. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV co-infected patients. J Acquire Immune Defic Syndr. 2008;49:61-3.
38. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: impact of nevirapine. AIDS. 2004;18:767-74. (Pubitemid 38535004)
39. Sterling RK, Wilson MS, Sanyal AJ, et al. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol. 2004;2:432-9. (Pubitemid 38561242)
40. Mehta S, Thomas DL, Toberson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005;41:123-31. (Pubitemid 40066390)
41. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182-9. (Pubitemid 34032559)
42. McGovern BH. Hepatic steatosis in IHV/HCV-coinfected patients: time to reevaluate! Gastroenterology. 2011;140:809-17.
43. Woreta TA, Stucliffe CG, Mehta AH, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and Hepatitis C virus. Gastroenterology. 2011;140:809-17.
44. Rodríguez-Nóvoa S, Morello J, González M, et al. Increase in serum bilirubin in HIV/hepatitis C virus-coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. AIDS. 2008;22:2535-7.
45. Gathe Jr JC, Pierone G, Piliero P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses. 2007;23:216-23. (Pubitemid 46418335)
46. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol. 2003;285:G949-958. (Pubitemid 37310074)
47. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119:1858-70.
48. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721-32. (Pubitemid 41552605)
49. Nasta P, Gatti F, Borghi F, et al. Liver stiffness (LS) change in HIV-Hepatitis C (HCV) coinfected patients treated with CCR5 inhibitor based antiretroviral therapy. [abstract H3-810]. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA; September 17-20, 2011.
50. Sulkowski M, Dietrich D, Sherman K, et al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN-a2a and RBV in HIV/HCV co-infected patients [abstract 146LB]. Presented at the 18th conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA; February 27-March 2, 2011.
51. Sherman KE, Rockstroh JK Dieterich, DT, et al. Telaprevir Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Coinfected Patients: 24-Week Treatment Interim Analysis. [abstract LB-8]. Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD). San Francisco, USA; November 4-8, 2011.
52. Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginter-feron/ ribavirin for the treatment of HCV/HIV co-infected patients: interim on-treatment results. [abstract LB-37]. Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA); Boston, USA; October 20-23, 2011.
53. Kasserra C, Hughes, E, Treitel M, et al. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions. [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA; February 27-March 2, 2011.
54. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-17.
55. Van Heeswijk RV, Boogaerts G, De Paepe E, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. [abstract 119]. 18th conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA; February 27-March 2, 2011.
56. Van Heeswijk R, Gysen V, Boogaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir. [abstract 966]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, USA; September 13-17, 2008.
57. Van Heeswijk R, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. [abstract A1-1738a]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA; September 17-20, 2011.